Leave your contact details and we will contact you
This year, physical consumption of emergency contraceptives in Russia is stagnating, although this is accompanied by an increase in the market's value volume. Notably, demand for these drugs intensifies during the summer vacation periods and official holidays.
In the retail segment of the Russian pharmaceutical market, a decline in physical demand for emergency contraceptives has been recorded for the second consecutive year. These products are represented by drugs containing the active ingredients levonorgestrel and mifepristone in specific dosages1. A noticeable reduction in sales volumes of these medications began after drugs containing mifepristone at a 10 mg dosage were included in the list of subject-quantitative registration in September 2024.
Based on the results of Q1–Q3 2026, physical consumption of postcoital drugs on the Russian retail market decreased by 0.5%, amounting to approximately 1.6 million packages during the period. At the same time, virtually the entire volume sold was accounted for by levonorgestrel, while mifepristone sales fell to less than 900 packages in total since the beginning of this year. Despite the negative dynamics of consumption in packages, consumer spending on this drug category continues to grow. During the reporting period, total pharmacy sales in monetary terms exceeded RUB 1.5 billion, which is 7.8% higher than in the same period of 2025.
According to the "Retail Audit of Drug Sales in Russia (total sell out)" from the analytical company RNC Pharma, an analysis of the monthly dynamics of retail sales of emergency contraceptives demonstrates pronounced seasonality of demand, with peaks that precisely coincide with vacation periods and national holidays. Over the past several years, maximum sales volumes have been consistently recorded in January, July, and August. In January of this year, for example, consumption volume amounted to 197 thousand packages, equivalent to RUB 177.2 million in monetary terms. In July, value indicators increased, reaching RUB 186.6 million. In August 2026, a four-year historical maximum in revenue volume was registered — consumer spending on postcoital contraceptives amounted to RUB 193.5 million. At the same time, the market volume in physical terms demonstrated moderate dynamics in this month and lagged behind previous periods: for comparison, in August 2023 and 2024, pharmacies sold about 207 thousand packages.
In contrast to the peak periods, minimum retail sales of emergency contraceptives are recorded annually in February. This year, for example, sales volume decreased to 156.4 thousand packages, equivalent to RUB 141 million in monetary terms. Already in March, sales rise sharply, which clearly correlates with the long weekends associated with International Women's Day. The next period of declining consumer demand for postcoital contraceptives traditionally forms at the end of the summer vacation season — in September. In the first month of autumn 2026, 178.2 thousand packages were sold at retail for a total of RUB 174.6 million.
In the retail segment of emergency contraceptives based on the INN levonorgestrel, only three brands were represented in Q1–Q3 of this year. Two of them (Escapelle and Postinor) are represented by Gedeon Richter, and one (Postiplania) by the domestic company Pharmasyntez. The only brand with positive physical dynamics was Escapelle: its sales grew by 6.3% in packages, and in monetary terms the brand showed growth of 14.4% in rubles. In the category of mifepristone-based drugs (10 mg), remaining stocks of the brands Genale (Izvarino Pharma) and Vneplania (Pharmasyntez) are being sold off in the market; their production was discontinued in February 2024 and November 2023, respectively.
Fig. Seasonal Characteristics of Demand for Emergency Contraceptives on the Russian Retail Pharmaceutical Market from January 2024 to September 2026, RUB million (at retail prices, including VAT)

[1] Analyzed drugs containing mifepristone at a dosage of 10 mg and levonorgestrel at dosages of 0.75 mg and 1.5 mg.
Leave your contact details and we will contact you